Janus Henderson Group PLC Has $23.61 Million Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Janus Henderson Group PLC raised its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 14.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,085,648 shares of the company's stock after purchasing an additional 136,314 shares during the quarter. Janus Henderson Group PLC owned 3.67% of Dianthus Therapeutics worth $23,607,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Deutsche Bank AG raised its stake in shares of Dianthus Therapeutics by 55.9% in the fourth quarter. Deutsche Bank AG now owns 20,011 shares of the company's stock valued at $436,000 after purchasing an additional 7,179 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Dianthus Therapeutics by 9.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 54,766 shares of the company's stock worth $1,194,000 after acquiring an additional 4,518 shares during the period. Braidwell LP lifted its holdings in shares of Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock worth $26,304,000 after acquiring an additional 712,902 shares during the period. BNP Paribas Financial Markets acquired a new position in Dianthus Therapeutics in the fourth quarter worth about $59,000. Finally, Allostery Investments LP bought a new position in Dianthus Therapeutics during the fourth quarter worth about $545,000. Institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Price Performance

Shares of DNTH stock traded down $0.42 on Monday, reaching $19.27. 248,258 shares of the stock were exchanged, compared to its average volume of 270,927. The stock has a 50 day moving average price of $19.40 and a 200 day moving average price of $22.07. The stock has a market cap of $619.72 million, a PE ratio of -7.71 and a beta of 1.48. Dianthus Therapeutics, Inc. has a one year low of $13.37 and a one year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million. On average, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on DNTH. Robert W. Baird reduced their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reiterated a "buy" rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.